List view / Grid view
Scientists have developed a genetic screening platform to identify genes that can enhance immune cells to make them more persistent and increase their ability to eradicate tumour cells.
Researchers have developed a pH-sensitive drug delivery system in T cells using C-terminal dendrimers with Phenylalanine.
Pre-clinical research has found that CAR T cells can suppress gastrointestinal cancer cells without causing harm to healthy tissues.
Researchers have created an implantable biotechnology that produces and releases CAR T cells for attacking cancerous tumours.
Research in mice has shown that adding anti-inflammatory medication to immunotherapy and standard chemotherapy drugs may provide long-term suppression of aggressive bladder tumour growth.
In this issue are articles on the development of mRNA vaccines against latent viruses, how memory B cell antibody-based treatments can help to fight cancer and the potential of AI in drug discovery. Also included are pieces on biotherapeutics, immuno-oncology and assays.
Scientists have discovered a new strategy that can make pancreatic tumours visible to the immune systems of mice and vulnerable to immune attack.
Scientists have discovered the essential role of a ligand-dependent corepressor to potentially enable cancer cells to present tumour antigens on their surfaces.
New research has discovered metabolic mechanisms that contribute to how ovarian cancer escapes from immune attack and how combination therapies can exploit these pathways to improve ovarian cancer treatment.
A new study has highlighted an enzyme called ART1 as a promising target for immunity-boosting cancer treatments.
A new study has highlighted that gene expression profiling could enable rapid identification of anti-tumour immune cells for personalised immunotherapy.
Scientists from Northwestern University have developed a new technology platform that could bring individualised cell therapies to cancer patients.
Scientists have found a way to “supercharge” tumour-attacking T cells, which could improve the effectiveness of cell-based cancer immunotherapy and expand the number of cancers it can treat.
A new CAR T-cell therapy for B-cell cancers promises to reduce the antigen escape currently found in therapies that only target CD19.
Dr Alasdair Gunn and Natalie Bath from Adaptimmune explain how flow cytometry provides a useful tool for the development of immuno-oncology therapies. They also explore how they use this method for translational research of the company’s SPEAR T-cell products.
